NucleoBond® Xtra Midi/Maxi EF

Plasmid DNA: transfection-grade to endotoxin-free

Contact

Please contact us for further information: support@mn-net.com

An ever-growing range of biochemical applications require medium to large amounts of plasmid DNA free of contamination with salts and residual bacterial components. With NucleoBond® Xtra yields of up to 500 µg (Midi) and up to 1000 µg (Maxi) of ultrapure plasmid DNA can be obtained based on reliable and well established anion exchange chromatography.

The NucleoBond® Xtra Midi/Maxi EF kits have a patented endotoxin removal which allows transfection of highly sensitive cells such as primary cells or stem cells. NucleoBond® Xtra Midi/Maxi kits contain enlarged columns, which lead to lower silica resin beds. This in turn enables faster flow of lysate and buffers through the columns. Specially designed column filters are included for convenient and timesaving clarification of bacterial lysates. The column filters are supplied inserted in the NucleoBond® Xtra Columns and allow parallel clarification of bacterial lysate and loading onto the column. Their large, structured surface leads to high filter flow rates and minimized risk of clogging. The following reference lists show latest publications from 2024 to 2026 for the NucleoBond® Xtra portfolio.

NucleoBond® Xtra Midi

Title	Year	Journal	DOI
Streamlining assays of glycosyltransferases activity using *in vitro* GT-array (*i*-GT-ray) platform: Application to family GT37 fucosyltransferases	2024	Journal of Biological Chemistry	10.1016/j.jbc.2024.105734
SOSHI-seq: a high-throughput screening assay to test the functionality of putative response elements for nuclear hormone receptors	2025	Scientific Reports	10.1038/s41598-025-29970-8
Key domains involved in the interaction and assembly of the HCMV terminase complex	2025	Scientific Reports	10.1038/s41598-025-28915-5
Systematic Evaluation of Vector Sequence Elements in Isogenic CHO Cells for Improved Antibody Production	2025	ACS Synthetic Biology	10.1021/acssynbio.5c00861

NucleoBond® Xtra Midi/Maxi EF reference list

NucleoBond® Xtra Midi EF

Title	Year	Journal	DOI
SelectRepair Knockout: Efficient PTC-Free Gene Knockout Through Selectable Homology-Directed DNA Repair	2025	Methods in Molecular Biology	10.1007/978-1-0716-4176-7_23
Screening of Sugarcane Proteins Associated with Defense against *Leifsonia xyli* subsp. *xyli*, Agent of Ratoon Stunting Disease	2024	Plants	10.3390/plants13030448
An Imbalance in Histone Modifiers Induces tRNA-Cys-GCA Overexpression and tRF-27 Accumulation by Attenuating Promoter H3K27me3 in Primary Trastuzumab-Resistant Breast Cancer	2024	Cancers	10.3390/cancers16061118
Unraveling productivity-enhancing genes in Chinese hamster ovary cells via CRISPR activation screening using recombinase-mediated cassette exchange system	2024	Metabolic Engineering	10.1016/j.ymben.2024.11.009

NucleoBond® Xtra Midi Plus

Title	Year	Journal	DOI
An immunoassay based on bioluminescent sensors for rapid detection of African swine fever virus antibodies	2024	Journal of Clinical Microbiology	10.1128/jcm.00463-24
MSH2 is not required for either maintenance of DNA methylation or repeat contraction at the FMR1 locus in fragile X syndrome or the FXN locus in Friedreich's ataxia	2025	Epigenetics & Chromatin	10.1186/s13072-025-00588-4
Upregulated small GTPase immunity-associated proteins confer resistance to *Neospora caninum* in rat and bovine cells	2025	Frontiers in Cellular and Infection Microbiology	10.3389/fcimb.2025.1674380
Directed evolution on compact landing pads yields highly efficient recombinases for large DNA integration	2026	Nucleic Acids research	10.1093/nar/gkaf1444

NucleoBond® Xtra Midi Plus EF

Title	Year	Journal	DOI
Engineering a "muco-trapping" ACE2-immunoglobulin hybrid with picomolar affinity as an inhaled, pan-variant immunotherapy for COVID-19	2024	Bioengineering & Translational Medicine	10.1002/btm2.10650
Characterization, Structure, and Inhibition of the Human Succinyl-CoA:glutarate-CoA Transferase, a Putative Genetic Modifier of Glutaric Aciduria Type 1	2025	ACS Chemical Biology	10.1021/acschembio.4c00204
Autophagy induction enhances homologous recombination-associated CRISPR-Cas9 gene editing	2025	Nucleic Acids Research	10.1093/nar/gkaf258
Preferential apical infection and spread of human metapneumovirus highlights the importance of inhaled delivery of neutralizing monoclonal antibody to treat established infections	2025	Proceedings of the National Academy of Sciences	10.1073/pnas.2502897122

NucleoBond® Xtra Maxi

Title	Year	Journal	DOI
NMR side-chain assignments of the Crimean-Congo hemorrhagic fever virus glycoprotein n cytosolic domain	2024	Magnetic Resonance	10.5194/mr-5-95-2024
Targeting the Exon2 splice *cis*-element in PD-1 and its effects on lymphocyte function	2025	PloS ONE	10.1371/journal.pone.0331468
Investigating the Role of A20 in Respiratory Syncytial Virus Immunopathogenesis in a BALB/c Mouse Model	2026	Immunity, Inflammation and Disease	10.1002/iid3.70337
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 *N*-Heptad Repeat	2025	ACS Chemical Biology	10.1021/acschembio.5c00035

NucleoBond® Xtra Midi/Maxi EF reference list

NucleoBond® Xtra Maxi EF

Title	Year	Journal	DOI
Well-differentiated systemic mastocytosis: Genetics, mast cell immunophenotypes, and KIT autophosphorylation	2025	Journal of Allergy and Clinical Immunology	10.1016/j.jaci.2025.07.029
Restoration of defective oxidative phosphorylation to a subset of neurons prevents mitochondrial encephalopathy	2024	EMBO Molecular Medicine	10.1038/s44321-024-00111-4
Comprehensive genome-scale CRISPR knockout screening of CHO cells	2025	Scientific Data	10.1038/s41597-025-04438-6
Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice	2025	PLoS ONE	10.1371/journal.pone.0318581

NucleoBond® Xtra Maxi Plus

Title	Year	Journal	DOI
Subunit-specific isotope labelling of heteromeric complexes using cell-free protein expression: application to the 760 kDa ClpXP molecular machine	2025	RSC Chemical Biology	10.1039/d5cb00259a
Evidence for NR2F2/COUP-TFII involvement in human testis development	2024	Scientific Reports	10.1038/s41598-024-68860-3
Toward site-specific characterization of structural perturbations on glycosylated Fc using NMR at natural abundance	2026	Journal of Biomolecular NMR	10.1007/s10858-025-00484-9
A fast and efficient strategy for the NMR assignment of Fab methyl groups	2026	Journal of Biomolecular NMR	10.1007/s10858-025-00480-z

NucleoBond® Xtra Maxi Plus EF

Title	Year	Journal	DOI
Inflammation-Triggering Engineered Macrophages (MacTriggers) Enhance Reactivity of Immune Checkpoint Inhibitor Only in Tumor Tissues	2024	Cancers	10.3390/cancers16223787
Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors	2025	Viruses	10.3390/v17030400
Pooled effector library screening in protoplasts rapidly identifies novel Avr genes	2024	Nature Plants	10.1038/s41477-024-01641-y
ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma	2026	Cancer Research	10.1158/0008-5472.CAN-24-4745

MACHEREY-NAGEL GmbH & Co. KG · Valencienner Str. 11 · 52355 Düren · Germany
DE +49 24 21 969-0 info@mn-net.com
CH +41 62 388 55 00 sales-ch@mn-net.com
FR +33 388 68 22 68 sales-fr@mn-net.com
US +1 888 321 62 24 sales-us@mn-net.com